Global Osteoarthritis Pain Drugs Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Osteoarthritis Pain Drugs market size is predicted to grow from US$ 10720 million in 2025 to US$ 15130 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.
The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.
The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.
LP Information, Inc. (LPI) ' newest research report, the “Osteoarthritis Pain Drugs Industry Forecast” looks at past sales and reviews total world Osteoarthritis Pain Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Osteoarthritis Pain Drugs sales for 2025 through 2031. With Osteoarthritis Pain Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoarthritis Pain Drugs industry.
This Insight Report provides a comprehensive analysis of the global Osteoarthritis Pain Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoarthritis Pain Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Osteoarthritis Pain Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoarthritis Pain Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoarthritis Pain Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Osteoarthritis Pain Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Osteoarthritis Pain Drugs market?
What factors are driving Osteoarthritis Pain Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Osteoarthritis Pain Drugs market opportunities vary by end market size?
How does Osteoarthritis Pain Drugs break out by Type, by Application?
The global Osteoarthritis Pain Drugs market size is predicted to grow from US$ 10720 million in 2025 to US$ 15130 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.
The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.
The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.
LP Information, Inc. (LPI) ' newest research report, the “Osteoarthritis Pain Drugs Industry Forecast” looks at past sales and reviews total world Osteoarthritis Pain Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Osteoarthritis Pain Drugs sales for 2025 through 2031. With Osteoarthritis Pain Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoarthritis Pain Drugs industry.
This Insight Report provides a comprehensive analysis of the global Osteoarthritis Pain Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoarthritis Pain Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Osteoarthritis Pain Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoarthritis Pain Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoarthritis Pain Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Osteoarthritis Pain Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral
- Injection
- External
- Medical Care
- Personal Care
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Bayer
- SK Chemicals
- GSK
- Sanofi
- Crystal Genomics
- Johnson & Johnson
- Sino Biopharmaceutical
- Haohai Biological
- Zhejiang Chengyi Pharmaceutical
- Freda
- Bright Future
- Jingfeng Pharmaceutical
- Chugai Pharmaceutical
- Mikasa Seiyaku
- Taisho Pharmaceutical
- Seikagaku Corporation
- GlaxoSmithKline
- Eli Lilly
- Novartis
- Horizon Pharma
- Abbott
- Mylan
- Daiichi Sankyo
- TEVA
- Almatica Pharma
- Astellas Pharma
- Tide Pharmaceutical
- Iroko Pharmaceuticals
- Hengrui Pharmaceutical
What is the 10-year outlook for the global Osteoarthritis Pain Drugs market?
What factors are driving Osteoarthritis Pain Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Osteoarthritis Pain Drugs market opportunities vary by end market size?
How does Osteoarthritis Pain Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Osteoarthritis Pain Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Osteoarthritis Pain Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Osteoarthritis Pain Drugs by Country/Region, 2020, 2024 & 2031
2.2 Osteoarthritis Pain Drugs Segment by Type
2.2.1 Oral
2.2.2 Injection
2.2.3 External
2.3 Osteoarthritis Pain Drugs Sales by Type
2.3.1 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Osteoarthritis Pain Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Osteoarthritis Pain Drugs Sale Price by Type (2020-2025)
2.4 Osteoarthritis Pain Drugs Segment by Application
2.4.1 Medical Care
2.4.2 Personal Care
2.5 Osteoarthritis Pain Drugs Sales by Application
2.5.1 Global Osteoarthritis Pain Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Osteoarthritis Pain Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Osteoarthritis Pain Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Osteoarthritis Pain Drugs Breakdown Data by Company
3.1.1 Global Osteoarthritis Pain Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Osteoarthritis Pain Drugs Sales Market Share by Company (2020-2025)
3.2 Global Osteoarthritis Pain Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Osteoarthritis Pain Drugs Revenue by Company (2020-2025)
3.2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Osteoarthritis Pain Drugs Sale Price by Company
3.4 Key Manufacturers Osteoarthritis Pain Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Osteoarthritis Pain Drugs Product Location Distribution
3.4.2 Players Osteoarthritis Pain Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OSTEOARTHRITIS PAIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Osteoarthritis Pain Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Osteoarthritis Pain Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Osteoarthritis Pain Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Osteoarthritis Pain Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Osteoarthritis Pain Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Osteoarthritis Pain Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Osteoarthritis Pain Drugs Sales Growth
4.4 APAC Osteoarthritis Pain Drugs Sales Growth
4.5 Europe Osteoarthritis Pain Drugs Sales Growth
4.6 Middle East & Africa Osteoarthritis Pain Drugs Sales Growth
5 AMERICAS
5.1 Americas Osteoarthritis Pain Drugs Sales by Country
5.1.1 Americas Osteoarthritis Pain Drugs Sales by Country (2020-2025)
5.1.2 Americas Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
5.2 Americas Osteoarthritis Pain Drugs Sales by Type (2020-2025)
5.3 Americas Osteoarthritis Pain Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osteoarthritis Pain Drugs Sales by Region
6.1.1 APAC Osteoarthritis Pain Drugs Sales by Region (2020-2025)
6.1.2 APAC Osteoarthritis Pain Drugs Revenue by Region (2020-2025)
6.2 APAC Osteoarthritis Pain Drugs Sales by Type (2020-2025)
6.3 APAC Osteoarthritis Pain Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Osteoarthritis Pain Drugs by Country
7.1.1 Europe Osteoarthritis Pain Drugs Sales by Country (2020-2025)
7.1.2 Europe Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
7.2 Europe Osteoarthritis Pain Drugs Sales by Type (2020-2025)
7.3 Europe Osteoarthritis Pain Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Osteoarthritis Pain Drugs by Country
8.1.1 Middle East & Africa Osteoarthritis Pain Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Osteoarthritis Pain Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Osteoarthritis Pain Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Osteoarthritis Pain Drugs
10.3 Manufacturing Process Analysis of Osteoarthritis Pain Drugs
10.4 Industry Chain Structure of Osteoarthritis Pain Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Osteoarthritis Pain Drugs Distributors
11.3 Osteoarthritis Pain Drugs Customer
12 WORLD FORECAST REVIEW FOR OSTEOARTHRITIS PAIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Osteoarthritis Pain Drugs Market Size Forecast by Region
12.1.1 Global Osteoarthritis Pain Drugs Forecast by Region (2026-2031)
12.1.2 Global Osteoarthritis Pain Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Osteoarthritis Pain Drugs Forecast by Type (2026-2031)
12.7 Global Osteoarthritis Pain Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 SK Chemicals
13.3.1 SK Chemicals Company Information
13.3.2 SK Chemicals Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 SK Chemicals Main Business Overview
13.3.5 SK Chemicals Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Crystal Genomics
13.6.1 Crystal Genomics Company Information
13.6.2 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Crystal Genomics Main Business Overview
13.6.5 Crystal Genomics Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Sino Biopharmaceutical
13.8.1 Sino Biopharmaceutical Company Information
13.8.2 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sino Biopharmaceutical Main Business Overview
13.8.5 Sino Biopharmaceutical Latest Developments
13.9 Haohai Biological
13.9.1 Haohai Biological Company Information
13.9.2 Haohai Biological Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Haohai Biological Main Business Overview
13.9.5 Haohai Biological Latest Developments
13.10 Zhejiang Chengyi Pharmaceutical
13.10.1 Zhejiang Chengyi Pharmaceutical Company Information
13.10.2 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zhejiang Chengyi Pharmaceutical Main Business Overview
13.10.5 Zhejiang Chengyi Pharmaceutical Latest Developments
13.11 Freda
13.11.1 Freda Company Information
13.11.2 Freda Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Freda Main Business Overview
13.11.5 Freda Latest Developments
13.12 Bright Future
13.12.1 Bright Future Company Information
13.12.2 Bright Future Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Bright Future Main Business Overview
13.12.5 Bright Future Latest Developments
13.13 Jingfeng Pharmaceutical
13.13.1 Jingfeng Pharmaceutical Company Information
13.13.2 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Jingfeng Pharmaceutical Main Business Overview
13.13.5 Jingfeng Pharmaceutical Latest Developments
13.14 Chugai Pharmaceutical
13.14.1 Chugai Pharmaceutical Company Information
13.14.2 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Chugai Pharmaceutical Main Business Overview
13.14.5 Chugai Pharmaceutical Latest Developments
13.15 Mikasa Seiyaku
13.15.1 Mikasa Seiyaku Company Information
13.15.2 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Mikasa Seiyaku Main Business Overview
13.15.5 Mikasa Seiyaku Latest Developments
13.16 Taisho Pharmaceutical
13.16.1 Taisho Pharmaceutical Company Information
13.16.2 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Taisho Pharmaceutical Main Business Overview
13.16.5 Taisho Pharmaceutical Latest Developments
13.17 Seikagaku Corporation
13.17.1 Seikagaku Corporation Company Information
13.17.2 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Seikagaku Corporation Main Business Overview
13.17.5 Seikagaku Corporation Latest Developments
13.18 GlaxoSmithKline
13.18.1 GlaxoSmithKline Company Information
13.18.2 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 GlaxoSmithKline Main Business Overview
13.18.5 GlaxoSmithKline Latest Developments
13.19 Eli Lilly
13.19.1 Eli Lilly Company Information
13.19.2 Eli Lilly Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Eli Lilly Main Business Overview
13.19.5 Eli Lilly Latest Developments
13.20 Novartis
13.20.1 Novartis Company Information
13.20.2 Novartis Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Novartis Main Business Overview
13.20.5 Novartis Latest Developments
13.21 Horizon Pharma
13.21.1 Horizon Pharma Company Information
13.21.2 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Horizon Pharma Main Business Overview
13.21.5 Horizon Pharma Latest Developments
13.22 Abbott
13.22.1 Abbott Company Information
13.22.2 Abbott Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Abbott Main Business Overview
13.22.5 Abbott Latest Developments
13.23 Mylan
13.23.1 Mylan Company Information
13.23.2 Mylan Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Mylan Main Business Overview
13.23.5 Mylan Latest Developments
13.24 Daiichi Sankyo
13.24.1 Daiichi Sankyo Company Information
13.24.2 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Daiichi Sankyo Main Business Overview
13.24.5 Daiichi Sankyo Latest Developments
13.25 TEVA
13.25.1 TEVA Company Information
13.25.2 TEVA Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 TEVA Main Business Overview
13.25.5 TEVA Latest Developments
13.26 Almatica Pharma
13.26.1 Almatica Pharma Company Information
13.26.2 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.26.4 Almatica Pharma Main Business Overview
13.26.5 Almatica Pharma Latest Developments
13.27 Astellas Pharma
13.27.1 Astellas Pharma Company Information
13.27.2 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.27.4 Astellas Pharma Main Business Overview
13.27.5 Astellas Pharma Latest Developments
13.28 Tide Pharmaceutical
13.28.1 Tide Pharmaceutical Company Information
13.28.2 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.28.4 Tide Pharmaceutical Main Business Overview
13.28.5 Tide Pharmaceutical Latest Developments
13.29 Iroko Pharmaceuticals
13.29.1 Iroko Pharmaceuticals Company Information
13.29.2 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.29.4 Iroko Pharmaceuticals Main Business Overview
13.29.5 Iroko Pharmaceuticals Latest Developments
13.30 Hengrui Pharmaceutical
13.30.1 Hengrui Pharmaceutical Company Information
13.30.2 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.30.4 Hengrui Pharmaceutical Main Business Overview
13.30.5 Hengrui Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Osteoarthritis Pain Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Osteoarthritis Pain Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Osteoarthritis Pain Drugs by Country/Region, 2020, 2024 & 2031
2.2 Osteoarthritis Pain Drugs Segment by Type
2.2.1 Oral
2.2.2 Injection
2.2.3 External
2.3 Osteoarthritis Pain Drugs Sales by Type
2.3.1 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Osteoarthritis Pain Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Osteoarthritis Pain Drugs Sale Price by Type (2020-2025)
2.4 Osteoarthritis Pain Drugs Segment by Application
2.4.1 Medical Care
2.4.2 Personal Care
2.5 Osteoarthritis Pain Drugs Sales by Application
2.5.1 Global Osteoarthritis Pain Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Osteoarthritis Pain Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Osteoarthritis Pain Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Osteoarthritis Pain Drugs Breakdown Data by Company
3.1.1 Global Osteoarthritis Pain Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Osteoarthritis Pain Drugs Sales Market Share by Company (2020-2025)
3.2 Global Osteoarthritis Pain Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Osteoarthritis Pain Drugs Revenue by Company (2020-2025)
3.2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Osteoarthritis Pain Drugs Sale Price by Company
3.4 Key Manufacturers Osteoarthritis Pain Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Osteoarthritis Pain Drugs Product Location Distribution
3.4.2 Players Osteoarthritis Pain Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OSTEOARTHRITIS PAIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Osteoarthritis Pain Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Osteoarthritis Pain Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Osteoarthritis Pain Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Osteoarthritis Pain Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Osteoarthritis Pain Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Osteoarthritis Pain Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Osteoarthritis Pain Drugs Sales Growth
4.4 APAC Osteoarthritis Pain Drugs Sales Growth
4.5 Europe Osteoarthritis Pain Drugs Sales Growth
4.6 Middle East & Africa Osteoarthritis Pain Drugs Sales Growth
5 AMERICAS
5.1 Americas Osteoarthritis Pain Drugs Sales by Country
5.1.1 Americas Osteoarthritis Pain Drugs Sales by Country (2020-2025)
5.1.2 Americas Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
5.2 Americas Osteoarthritis Pain Drugs Sales by Type (2020-2025)
5.3 Americas Osteoarthritis Pain Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osteoarthritis Pain Drugs Sales by Region
6.1.1 APAC Osteoarthritis Pain Drugs Sales by Region (2020-2025)
6.1.2 APAC Osteoarthritis Pain Drugs Revenue by Region (2020-2025)
6.2 APAC Osteoarthritis Pain Drugs Sales by Type (2020-2025)
6.3 APAC Osteoarthritis Pain Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Osteoarthritis Pain Drugs by Country
7.1.1 Europe Osteoarthritis Pain Drugs Sales by Country (2020-2025)
7.1.2 Europe Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
7.2 Europe Osteoarthritis Pain Drugs Sales by Type (2020-2025)
7.3 Europe Osteoarthritis Pain Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Osteoarthritis Pain Drugs by Country
8.1.1 Middle East & Africa Osteoarthritis Pain Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Osteoarthritis Pain Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Osteoarthritis Pain Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Osteoarthritis Pain Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Osteoarthritis Pain Drugs
10.3 Manufacturing Process Analysis of Osteoarthritis Pain Drugs
10.4 Industry Chain Structure of Osteoarthritis Pain Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Osteoarthritis Pain Drugs Distributors
11.3 Osteoarthritis Pain Drugs Customer
12 WORLD FORECAST REVIEW FOR OSTEOARTHRITIS PAIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Osteoarthritis Pain Drugs Market Size Forecast by Region
12.1.1 Global Osteoarthritis Pain Drugs Forecast by Region (2026-2031)
12.1.2 Global Osteoarthritis Pain Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Osteoarthritis Pain Drugs Forecast by Type (2026-2031)
12.7 Global Osteoarthritis Pain Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 SK Chemicals
13.3.1 SK Chemicals Company Information
13.3.2 SK Chemicals Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 SK Chemicals Main Business Overview
13.3.5 SK Chemicals Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Crystal Genomics
13.6.1 Crystal Genomics Company Information
13.6.2 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Crystal Genomics Main Business Overview
13.6.5 Crystal Genomics Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Sino Biopharmaceutical
13.8.1 Sino Biopharmaceutical Company Information
13.8.2 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sino Biopharmaceutical Main Business Overview
13.8.5 Sino Biopharmaceutical Latest Developments
13.9 Haohai Biological
13.9.1 Haohai Biological Company Information
13.9.2 Haohai Biological Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Haohai Biological Main Business Overview
13.9.5 Haohai Biological Latest Developments
13.10 Zhejiang Chengyi Pharmaceutical
13.10.1 Zhejiang Chengyi Pharmaceutical Company Information
13.10.2 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zhejiang Chengyi Pharmaceutical Main Business Overview
13.10.5 Zhejiang Chengyi Pharmaceutical Latest Developments
13.11 Freda
13.11.1 Freda Company Information
13.11.2 Freda Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Freda Main Business Overview
13.11.5 Freda Latest Developments
13.12 Bright Future
13.12.1 Bright Future Company Information
13.12.2 Bright Future Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Bright Future Main Business Overview
13.12.5 Bright Future Latest Developments
13.13 Jingfeng Pharmaceutical
13.13.1 Jingfeng Pharmaceutical Company Information
13.13.2 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Jingfeng Pharmaceutical Main Business Overview
13.13.5 Jingfeng Pharmaceutical Latest Developments
13.14 Chugai Pharmaceutical
13.14.1 Chugai Pharmaceutical Company Information
13.14.2 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Chugai Pharmaceutical Main Business Overview
13.14.5 Chugai Pharmaceutical Latest Developments
13.15 Mikasa Seiyaku
13.15.1 Mikasa Seiyaku Company Information
13.15.2 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Mikasa Seiyaku Main Business Overview
13.15.5 Mikasa Seiyaku Latest Developments
13.16 Taisho Pharmaceutical
13.16.1 Taisho Pharmaceutical Company Information
13.16.2 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Taisho Pharmaceutical Main Business Overview
13.16.5 Taisho Pharmaceutical Latest Developments
13.17 Seikagaku Corporation
13.17.1 Seikagaku Corporation Company Information
13.17.2 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Seikagaku Corporation Main Business Overview
13.17.5 Seikagaku Corporation Latest Developments
13.18 GlaxoSmithKline
13.18.1 GlaxoSmithKline Company Information
13.18.2 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 GlaxoSmithKline Main Business Overview
13.18.5 GlaxoSmithKline Latest Developments
13.19 Eli Lilly
13.19.1 Eli Lilly Company Information
13.19.2 Eli Lilly Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Eli Lilly Main Business Overview
13.19.5 Eli Lilly Latest Developments
13.20 Novartis
13.20.1 Novartis Company Information
13.20.2 Novartis Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Novartis Main Business Overview
13.20.5 Novartis Latest Developments
13.21 Horizon Pharma
13.21.1 Horizon Pharma Company Information
13.21.2 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Horizon Pharma Main Business Overview
13.21.5 Horizon Pharma Latest Developments
13.22 Abbott
13.22.1 Abbott Company Information
13.22.2 Abbott Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Abbott Main Business Overview
13.22.5 Abbott Latest Developments
13.23 Mylan
13.23.1 Mylan Company Information
13.23.2 Mylan Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Mylan Main Business Overview
13.23.5 Mylan Latest Developments
13.24 Daiichi Sankyo
13.24.1 Daiichi Sankyo Company Information
13.24.2 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Daiichi Sankyo Main Business Overview
13.24.5 Daiichi Sankyo Latest Developments
13.25 TEVA
13.25.1 TEVA Company Information
13.25.2 TEVA Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 TEVA Main Business Overview
13.25.5 TEVA Latest Developments
13.26 Almatica Pharma
13.26.1 Almatica Pharma Company Information
13.26.2 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.26.4 Almatica Pharma Main Business Overview
13.26.5 Almatica Pharma Latest Developments
13.27 Astellas Pharma
13.27.1 Astellas Pharma Company Information
13.27.2 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.27.4 Astellas Pharma Main Business Overview
13.27.5 Astellas Pharma Latest Developments
13.28 Tide Pharmaceutical
13.28.1 Tide Pharmaceutical Company Information
13.28.2 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.28.4 Tide Pharmaceutical Main Business Overview
13.28.5 Tide Pharmaceutical Latest Developments
13.29 Iroko Pharmaceuticals
13.29.1 Iroko Pharmaceuticals Company Information
13.29.2 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.29.4 Iroko Pharmaceuticals Main Business Overview
13.29.5 Iroko Pharmaceuticals Latest Developments
13.30 Hengrui Pharmaceutical
13.30.1 Hengrui Pharmaceutical Company Information
13.30.2 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
13.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.30.4 Hengrui Pharmaceutical Main Business Overview
13.30.5 Hengrui Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Osteoarthritis Pain Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Osteoarthritis Pain Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Injection
Table 5. Major Players of External
Table 6. Global Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 7. Global Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Table 8. Global Osteoarthritis Pain Drugs Revenue byType (2020-2025) & ($ million)
Table 9. Global Osteoarthritis Pain Drugs Revenue Market Share byType (2020-2025)
Table 10. Global Osteoarthritis Pain Drugs Sale Price byType (2020-2025) & (USD/Unit)
Table 11. Global Osteoarthritis Pain Drugs Sale by Application (2020-2025) & (K Units)
Table 12. Global Osteoarthritis Pain Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Osteoarthritis Pain Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Osteoarthritis Pain Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Osteoarthritis Pain Drugs Sales by Company (2020-2025) & (K Units)
Table 17. Global Osteoarthritis Pain Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Osteoarthritis Pain Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Osteoarthritis Pain Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Osteoarthritis Pain Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Osteoarthritis Pain Drugs Producing Area Distribution and Sales Area
Table 22. Players Osteoarthritis Pain Drugs Products Offered
Table 23. Osteoarthritis Pain Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Osteoarthritis Pain Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Osteoarthritis Pain Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Osteoarthritis Pain Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Osteoarthritis Pain Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Osteoarthritis Pain Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Osteoarthritis Pain Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Osteoarthritis Pain Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 35. Americas Osteoarthritis Pain Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Osteoarthritis Pain Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 38. Americas Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 39. APAC Osteoarthritis Pain Drugs Sales by Region (2020-2025) & (K Units)
Table 40. APAC Osteoarthritis Pain Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Osteoarthritis Pain Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 43. APAC Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 44. Europe Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 45. Europe Osteoarthritis Pain Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 47. Europe Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Osteoarthritis Pain Drugs
Table 53. Key Market Challenges & Risks of Osteoarthritis Pain Drugs
Table 54. Key IndustryTrends of Osteoarthritis Pain Drugs
Table 55. Osteoarthritis Pain Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Osteoarthritis Pain Drugs Distributors List
Table 58. Osteoarthritis Pain Drugs Customer List
Table 59. Global Osteoarthritis Pain Drugs SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Osteoarthritis Pain Drugs RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Osteoarthritis Pain Drugs Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Osteoarthritis Pain Drugs SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Osteoarthritis Pain Drugs Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Osteoarthritis Pain Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Osteoarthritis Pain Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Osteoarthritis Pain Drugs SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Osteoarthritis Pain Drugs RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Osteoarthritis Pain Drugs SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Osteoarthritis Pain Drugs RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 75. Pfizer Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Bayer Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 80. Bayer Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. SK Chemicals Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. SK Chemicals Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 85. SK Chemicals Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. SK Chemicals Main Business
Table 87. SK Chemicals Latest Developments
Table 88. GSK Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 90. GSK Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. Sanofi Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Sanofi Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 95. Sanofi Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Sanofi Main Business
Table 97. Sanofi Latest Developments
Table 98. Crystal Genomics Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 100. Crystal Genomics Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Crystal Genomics Main Business
Table 102. Crystal Genomics Latest Developments
Table 103. Johnson & Johnson Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 105. Johnson & Johnson Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Johnson & Johnson Main Business
Table 107. Johnson & Johnson Latest Developments
Table 108. Sino Biopharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 110. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Sino Biopharmaceutical Main Business
Table 112. Sino Biopharmaceutical Latest Developments
Table 113. Haohai Biological Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Haohai Biological Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 115. Haohai Biological Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Haohai Biological Main Business
Table 117. Haohai Biological Latest Developments
Table 118. Zhejiang Chengyi Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 120. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Zhejiang Chengyi Pharmaceutical Main Business
Table 122. Zhejiang Chengyi Pharmaceutical Latest Developments
Table 123.Freda Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124.Freda Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 125.Freda Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126.Freda Main Business
Table 127.Freda Latest Developments
Table 128. BrightFuture Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. BrightFuture Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 130. BrightFuture Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. BrightFuture Main Business
Table 132. BrightFuture Latest Developments
Table 133. Jingfeng Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 135. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 136. Jingfeng Pharmaceutical Main Business
Table 137. Jingfeng Pharmaceutical Latest Developments
Table 138. Chugai Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 140. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 141. Chugai Pharmaceutical Main Business
Table 142. Chugai Pharmaceutical Latest Developments
Table 143. Mikasa Seiyaku Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 145. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 146. Mikasa Seiyaku Main Business
Table 147. Mikasa Seiyaku Latest Developments
Table 148.Taisho Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149.Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 150.Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 151.Taisho Pharmaceutical Main Business
Table 152.Taisho Pharmaceutical Latest Developments
Table 153. Seikagaku Corporation Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 155. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 156. Seikagaku Corporation Main Business
Table 157. Seikagaku Corporation Latest Developments
Table 158. GlaxoSmithKline Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 160. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 161. GlaxoSmithKline Main Business
Table 162. GlaxoSmithKline Latest Developments
Table 163. Eli Lilly Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Eli Lilly Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 165. Eli Lilly Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 166. Eli Lilly Main Business
Table 167. Eli Lilly Latest Developments
Table 168. Novartis Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Novartis Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 170. Novartis Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 171. Novartis Main Business
Table 172. Novartis Latest Developments
Table 173. Horizon Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 174. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 175. Horizon Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 176. Horizon Pharma Main Business
Table 177. Horizon Pharma Latest Developments
Table 178. Abbott Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 179. Abbott Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 180. Abbott Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 181. Abbott Main Business
Table 182. Abbott Latest Developments
Table 183. Mylan Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 184. Mylan Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 185. Mylan Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 186. Mylan Main Business
Table 187. Mylan Latest Developments
Table 188. Daiichi Sankyo Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 189. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 190. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 191. Daiichi Sankyo Main Business
Table 192. Daiichi Sankyo Latest Developments
Table 193.TEVA Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 194.TEVA Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 195.TEVA Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 196.TEVA Main Business
Table 197.TEVA Latest Developments
Table 198. Almatica Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 199. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 200. Almatica Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 201. Almatica Pharma Main Business
Table 202. Almatica Pharma Latest Developments
Table 203. Astellas Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 204. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 205. Astellas Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 206. Astellas Pharma Main Business
Table 207. Astellas Pharma Latest Developments
Table 208.Tide Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 209.Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 210.Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 211.Tide Pharmaceutical Main Business
Table 212.Tide Pharmaceutical Latest Developments
Table 213. Iroko Pharmaceuticals Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 214. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 215. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 216. Iroko Pharmaceuticals Main Business
Table 217. Iroko Pharmaceuticals Latest Developments
Table 218. Hengrui Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 219. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 220. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 221. Hengrui Pharmaceutical Main Business
Table 222. Hengrui Pharmaceutical Latest Developments
Table 1. Osteoarthritis Pain Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Osteoarthritis Pain Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Injection
Table 5. Major Players of External
Table 6. Global Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 7. Global Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Table 8. Global Osteoarthritis Pain Drugs Revenue byType (2020-2025) & ($ million)
Table 9. Global Osteoarthritis Pain Drugs Revenue Market Share byType (2020-2025)
Table 10. Global Osteoarthritis Pain Drugs Sale Price byType (2020-2025) & (USD/Unit)
Table 11. Global Osteoarthritis Pain Drugs Sale by Application (2020-2025) & (K Units)
Table 12. Global Osteoarthritis Pain Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Osteoarthritis Pain Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Osteoarthritis Pain Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Osteoarthritis Pain Drugs Sales by Company (2020-2025) & (K Units)
Table 17. Global Osteoarthritis Pain Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Osteoarthritis Pain Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Osteoarthritis Pain Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Osteoarthritis Pain Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Osteoarthritis Pain Drugs Producing Area Distribution and Sales Area
Table 22. Players Osteoarthritis Pain Drugs Products Offered
Table 23. Osteoarthritis Pain Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Osteoarthritis Pain Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Osteoarthritis Pain Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Osteoarthritis Pain Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Osteoarthritis Pain Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Osteoarthritis Pain Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Osteoarthritis Pain Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Osteoarthritis Pain Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 35. Americas Osteoarthritis Pain Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Osteoarthritis Pain Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 38. Americas Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 39. APAC Osteoarthritis Pain Drugs Sales by Region (2020-2025) & (K Units)
Table 40. APAC Osteoarthritis Pain Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Osteoarthritis Pain Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 43. APAC Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 44. Europe Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 45. Europe Osteoarthritis Pain Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 47. Europe Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Osteoarthritis Pain Drugs Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Osteoarthritis Pain Drugs Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Osteoarthritis Pain Drugs Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Osteoarthritis Pain Drugs
Table 53. Key Market Challenges & Risks of Osteoarthritis Pain Drugs
Table 54. Key IndustryTrends of Osteoarthritis Pain Drugs
Table 55. Osteoarthritis Pain Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Osteoarthritis Pain Drugs Distributors List
Table 58. Osteoarthritis Pain Drugs Customer List
Table 59. Global Osteoarthritis Pain Drugs SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Osteoarthritis Pain Drugs RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Osteoarthritis Pain Drugs Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Osteoarthritis Pain Drugs SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Osteoarthritis Pain Drugs Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Osteoarthritis Pain Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Osteoarthritis Pain Drugs SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Osteoarthritis Pain Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Osteoarthritis Pain Drugs SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Osteoarthritis Pain Drugs RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Osteoarthritis Pain Drugs SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Osteoarthritis Pain Drugs RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. Pfizer Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 75. Pfizer Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Bayer Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 80. Bayer Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. SK Chemicals Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. SK Chemicals Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 85. SK Chemicals Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. SK Chemicals Main Business
Table 87. SK Chemicals Latest Developments
Table 88. GSK Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. GSK Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 90. GSK Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. GSK Main Business
Table 92. GSK Latest Developments
Table 93. Sanofi Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Sanofi Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 95. Sanofi Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Sanofi Main Business
Table 97. Sanofi Latest Developments
Table 98. Crystal Genomics Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 100. Crystal Genomics Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Crystal Genomics Main Business
Table 102. Crystal Genomics Latest Developments
Table 103. Johnson & Johnson Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 105. Johnson & Johnson Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Johnson & Johnson Main Business
Table 107. Johnson & Johnson Latest Developments
Table 108. Sino Biopharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 110. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Sino Biopharmaceutical Main Business
Table 112. Sino Biopharmaceutical Latest Developments
Table 113. Haohai Biological Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Haohai Biological Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 115. Haohai Biological Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Haohai Biological Main Business
Table 117. Haohai Biological Latest Developments
Table 118. Zhejiang Chengyi Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 120. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Zhejiang Chengyi Pharmaceutical Main Business
Table 122. Zhejiang Chengyi Pharmaceutical Latest Developments
Table 123.Freda Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124.Freda Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 125.Freda Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126.Freda Main Business
Table 127.Freda Latest Developments
Table 128. BrightFuture Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. BrightFuture Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 130. BrightFuture Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. BrightFuture Main Business
Table 132. BrightFuture Latest Developments
Table 133. Jingfeng Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 135. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 136. Jingfeng Pharmaceutical Main Business
Table 137. Jingfeng Pharmaceutical Latest Developments
Table 138. Chugai Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 140. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 141. Chugai Pharmaceutical Main Business
Table 142. Chugai Pharmaceutical Latest Developments
Table 143. Mikasa Seiyaku Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 145. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 146. Mikasa Seiyaku Main Business
Table 147. Mikasa Seiyaku Latest Developments
Table 148.Taisho Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149.Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 150.Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 151.Taisho Pharmaceutical Main Business
Table 152.Taisho Pharmaceutical Latest Developments
Table 153. Seikagaku Corporation Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 155. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 156. Seikagaku Corporation Main Business
Table 157. Seikagaku Corporation Latest Developments
Table 158. GlaxoSmithKline Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 160. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 161. GlaxoSmithKline Main Business
Table 162. GlaxoSmithKline Latest Developments
Table 163. Eli Lilly Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Eli Lilly Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 165. Eli Lilly Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 166. Eli Lilly Main Business
Table 167. Eli Lilly Latest Developments
Table 168. Novartis Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Novartis Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 170. Novartis Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 171. Novartis Main Business
Table 172. Novartis Latest Developments
Table 173. Horizon Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 174. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 175. Horizon Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 176. Horizon Pharma Main Business
Table 177. Horizon Pharma Latest Developments
Table 178. Abbott Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 179. Abbott Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 180. Abbott Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 181. Abbott Main Business
Table 182. Abbott Latest Developments
Table 183. Mylan Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 184. Mylan Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 185. Mylan Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 186. Mylan Main Business
Table 187. Mylan Latest Developments
Table 188. Daiichi Sankyo Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 189. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 190. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 191. Daiichi Sankyo Main Business
Table 192. Daiichi Sankyo Latest Developments
Table 193.TEVA Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 194.TEVA Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 195.TEVA Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 196.TEVA Main Business
Table 197.TEVA Latest Developments
Table 198. Almatica Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 199. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 200. Almatica Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 201. Almatica Pharma Main Business
Table 202. Almatica Pharma Latest Developments
Table 203. Astellas Pharma Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 204. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 205. Astellas Pharma Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 206. Astellas Pharma Main Business
Table 207. Astellas Pharma Latest Developments
Table 208.Tide Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 209.Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 210.Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 211.Tide Pharmaceutical Main Business
Table 212.Tide Pharmaceutical Latest Developments
Table 213. Iroko Pharmaceuticals Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 214. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 215. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 216. Iroko Pharmaceuticals Main Business
Table 217. Iroko Pharmaceuticals Latest Developments
Table 218. Hengrui Pharmaceutical Basic Information, Osteoarthritis Pain Drugs Manufacturing Base, Sales Area and Its Competitors
Table 219. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolios and Specifications
Table 220. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 221. Hengrui Pharmaceutical Main Business
Table 222. Hengrui Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Osteoarthritis Pain Drugs
Figure 2. Osteoarthritis Pain Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Osteoarthritis Pain Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Osteoarthritis Pain Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Osteoarthritis Pain Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2024)
Figure 10. Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Injection
Figure 13. Product Picture of External
Figure 14. Global Osteoarthritis Pain Drugs Sales Market Share byType in 2025
Figure 15. Global Osteoarthritis Pain Drugs Revenue Market Share byType (2020-2025)
Figure 16. Osteoarthritis Pain Drugs Consumed in Medical Care
Figure 17. Global Osteoarthritis Pain Drugs Market: Medical Care (2020-2025) & (K Units)
Figure 18. Osteoarthritis Pain Drugs Consumed in Personal Care
Figure 19. Global Osteoarthritis Pain Drugs Market: Personal Care (2020-2025) & (K Units)
Figure 20. Global Osteoarthritis Pain Drugs Sale Market Share by Application (2024)
Figure 21. Global Osteoarthritis Pain Drugs Revenue Market Share by Application in 2025
Figure 22. Osteoarthritis Pain Drugs Sales by Company in 2025 (K Units)
Figure 23. Global Osteoarthritis Pain Drugs Sales Market Share by Company in 2025
Figure 24. Osteoarthritis Pain Drugs Revenue by Company in 2025 ($ millions)
Figure 25. Global Osteoarthritis Pain Drugs Revenue Market Share by Company in 2025
Figure 26. Global Osteoarthritis Pain Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global Osteoarthritis Pain Drugs Revenue Market Share by Geographic Region in 2025
Figure 28. Americas Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 29. Americas Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 30. APAC Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 31. APAC Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 32. Europe Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 33. Europe Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 36. Americas Osteoarthritis Pain Drugs Sales Market Share by Country in 2025
Figure 37. Americas Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Figure 38. Americas Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 39. Americas Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 40. United States Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC Osteoarthritis Pain Drugs Sales Market Share by Region in 2025
Figure 45. APAC Osteoarthritis Pain Drugs Revenue Market Share by Region (2020-2025)
Figure 46. APAC Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 47. APAC Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 48. China Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. India Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. ChinaTaiwan Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe Osteoarthritis Pain Drugs Sales Market Share by Country in 2025
Figure 56. Europe Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Figure 57. Europe Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 58. Europe Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 59. Germany Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60.France Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. UK Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 66. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 67. Egypt Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70.Turkey Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Osteoarthritis Pain Drugs in 2025
Figure 73. Manufacturing Process Analysis of Osteoarthritis Pain Drugs
Figure 74. Industry Chain Structure of Osteoarthritis Pain Drugs
Figure 75. Channels of Distribution
Figure 76. Global Osteoarthritis Pain Drugs Sales MarketForecast by Region (2026-2031)
Figure 77. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast by Region (2026-2031)
Figure 78. Global Osteoarthritis Pain Drugs Sales Market ShareForecast byType (2026-2031)
Figure 79. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast byType (2026-2031)
Figure 80. Global Osteoarthritis Pain Drugs Sales Market ShareForecast by Application (2026-2031)
Figure 81. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast by Application (2026-2031)
Figure 1. Picture of Osteoarthritis Pain Drugs
Figure 2. Osteoarthritis Pain Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Osteoarthritis Pain Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Osteoarthritis Pain Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Osteoarthritis Pain Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2024)
Figure 10. Osteoarthritis Pain Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Injection
Figure 13. Product Picture of External
Figure 14. Global Osteoarthritis Pain Drugs Sales Market Share byType in 2025
Figure 15. Global Osteoarthritis Pain Drugs Revenue Market Share byType (2020-2025)
Figure 16. Osteoarthritis Pain Drugs Consumed in Medical Care
Figure 17. Global Osteoarthritis Pain Drugs Market: Medical Care (2020-2025) & (K Units)
Figure 18. Osteoarthritis Pain Drugs Consumed in Personal Care
Figure 19. Global Osteoarthritis Pain Drugs Market: Personal Care (2020-2025) & (K Units)
Figure 20. Global Osteoarthritis Pain Drugs Sale Market Share by Application (2024)
Figure 21. Global Osteoarthritis Pain Drugs Revenue Market Share by Application in 2025
Figure 22. Osteoarthritis Pain Drugs Sales by Company in 2025 (K Units)
Figure 23. Global Osteoarthritis Pain Drugs Sales Market Share by Company in 2025
Figure 24. Osteoarthritis Pain Drugs Revenue by Company in 2025 ($ millions)
Figure 25. Global Osteoarthritis Pain Drugs Revenue Market Share by Company in 2025
Figure 26. Global Osteoarthritis Pain Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global Osteoarthritis Pain Drugs Revenue Market Share by Geographic Region in 2025
Figure 28. Americas Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 29. Americas Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 30. APAC Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 31. APAC Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 32. Europe Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 33. Europe Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa Osteoarthritis Pain Drugs Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa Osteoarthritis Pain Drugs Revenue 2020-2025 ($ millions)
Figure 36. Americas Osteoarthritis Pain Drugs Sales Market Share by Country in 2025
Figure 37. Americas Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Figure 38. Americas Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 39. Americas Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 40. United States Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC Osteoarthritis Pain Drugs Sales Market Share by Region in 2025
Figure 45. APAC Osteoarthritis Pain Drugs Revenue Market Share by Region (2020-2025)
Figure 46. APAC Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 47. APAC Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 48. China Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. India Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. ChinaTaiwan Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe Osteoarthritis Pain Drugs Sales Market Share by Country in 2025
Figure 56. Europe Osteoarthritis Pain Drugs Revenue Market Share by Country (2020-2025)
Figure 57. Europe Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 58. Europe Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 59. Germany Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60.France Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. UK Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share byType (2020-2025)
Figure 66. Middle East & Africa Osteoarthritis Pain Drugs Sales Market Share by Application (2020-2025)
Figure 67. Egypt Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70.Turkey Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries Osteoarthritis Pain Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Osteoarthritis Pain Drugs in 2025
Figure 73. Manufacturing Process Analysis of Osteoarthritis Pain Drugs
Figure 74. Industry Chain Structure of Osteoarthritis Pain Drugs
Figure 75. Channels of Distribution
Figure 76. Global Osteoarthritis Pain Drugs Sales MarketForecast by Region (2026-2031)
Figure 77. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast by Region (2026-2031)
Figure 78. Global Osteoarthritis Pain Drugs Sales Market ShareForecast byType (2026-2031)
Figure 79. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast byType (2026-2031)
Figure 80. Global Osteoarthritis Pain Drugs Sales Market ShareForecast by Application (2026-2031)
Figure 81. Global Osteoarthritis Pain Drugs Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Hypnotics Market Growth 2025-2031
US$ 3,660.00
December 2025
115 pages
Global Transplantation Preservation Solutions Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
119 pages
